NeuroSense's PrimeC, a fixed-dose combination of ciprofloxacin and celecoxib, demonstrated favorable safety and directionally consistent biomarker shifts in a small 12-month Phase 2 study of Alzheimer's disease, including reductions in tau phosphorylation, amyloid-beta alterations, and inflammation markers. The findings support progression to a larger, adequately powered trial but remain preliminary and exploratory.
Key Points
- PrimeC showed favorable safety with no serious adverse events
- Plasma biomarkers shifted toward reduced tau and amyloid pathology
- Multi-target mechanism addressed oxidative stress and inflammation simultaneously
Longevity Analysis
The biomarker patterns suggest PrimeC addresses multiple pathological drivers of neurodegeneration rather than a single target—a distinction relevant to how the brain's defensive and detoxification capacity can be supported when multiple pathways contribute to disease. The favorable safety profile in a combination approach suggests that strategic simultaneous intervention on tau, amyloid, and neuroinflammation may reduce the tolerability burden that has limited single-agent therapies. These early signals warrant validation in adequately powered studies, as biomarker proximity to clinical outcomes in Alzheimer's remains imperfect; the therapeutic significance depends on whether plasma changes translate to slowed cognitive decline.
Original published by LT Wire.